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Vasculitis is rare in children [1]. Henoch-Schonlein purpura (HSP) followed by Kawasaki disease is the most common systemic vasculitis in the pediatric population [2]. The 
American College of Rheumatology classification of vasculitis 
(ACR criteria 1994) did not include children [3]. However, 
still, the ACR criteria were used for many years for diagnosis of 
vasculitis in children. In 2005, the vasculitis working group of 
the pediatric rheumatology European society (PRES) proposed 
preliminary classification criteria [4]. Chapel Hill Consensus 
Conference on the Nomenclature of systemic vasculitides in 
2012 renamed HSP to immunoglobulin A vasculitis, due to the 
deposition of IgA in the vessel wall which is pathognomonic [5]. 
It affects the small blood vessels of the skin and gastrointestinal 
(GI) tract, kidney, and joints.
HSP is a benign and self-limiting disease with an excellent 
prognosis. It takes around 4 weeks for recovery in two-thirds of 
patients. The disease may recur within the first 4 weeks to as late 
as 2 years after onset in a third to half of the cases. Although the 
clinicopathological profile of HSP has been studied before, data 
from the eastern part of our country are lacking. Hence, this study 
was planned to evaluate the clinico-epidemiological profile, 
response to the available therapeutic agents and complications of 
the disease.
MATERIALS AND METHODS
A retrograde review of the medical records of 35 children 
diagnosed with HSP, from January 2016 to June 2018, was 
performed at Kalinga Institute of Medical Sciences. A total 
number of 35 patients of purpura were identified from the 
records. The inclusion criteria were children with palpable 
purpura in the absence of coagulopathy and thrombocytopenia 
with the presence of at least one of the following features such 
as diffuse abdominal pain, any biopsy showing predominant IgA 
deposition, arthritis or arthralgia, and renal involvement in the 
form of hematuria and/or proteinuria. Purpura associated with 
other collagen vascular disorders, incomplete medical records, 
incorrect coding and cases of more than 1 month after initial 
diagnosis at another hospital were excluded from the study.
Out of the 35 patients, eight were excluded from the study; 
two had presented more than 1 month after initial diagnosis at 
another hospital, the medical record was incomplete in three 
patients, purpura was due to other collagen vascular disorder 
in two cases, and there was incorrect coding in one patient. 
Diagnosis of HSP was based on criteria laid by the European 
League Against Rheumatism endorsed consensus criteria for HSP 
proposed by Ozen et al. [4]. The criteria include palpable purpura 
which is a mandatory criterion with the presence of at least one of 
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the following features such as diffuse abdominal pain, any biopsy 
showing predominant IgA deposition, arthritis or arthralgia, and 
renal involvement in the form of hematuria and/or proteinuria.
Abdominal pain was grouped into two types among which 
one category included severe pain in abdomen requiring a 
radiological examination to exclude other surgical causes and 
the other one being mild pain in abdomen. Renal involvement 
included hematuria (>5 red blood cells/hpf) and proteinuria (urine 
protein creatinine ratio, Upr:Ucr >0.2). In the included patients, 
the data collected included age, gender, clinical presentations, 
and findings. Laboratory data including complete blood count, 
C-reactive protein, erythrocyte sedimentation rate (ESR), 
complete urinalysis, ultrasound abdomen, and duration of steroid 
treatment. The treatment was given according to the severity of 
the disease with oral or injectable steroids or immunosuppressive 
drugs. Response to steroid treatment was analyzed in 25 patients 
who were followed up for 6 months period, after exclusion of two 
patients who did not merit steroid treatment.
All statistical analysis was performed with SPSS version 18.0. 
Continuous variables were expressed as mean±standard deviation. 
Categorical variables were expressed as a percentage. Fisher’s 
exact test was used to evaluate the difference between responses 
to oral and injectable steroids. p<0.05 was considered statistically 
significant.
RESULTS
In the 2 ½ years study duration, 27 patients were included in the 
study. The average age of onset of disease was 7.3 (7.27±2.65) 
years, the youngest patient being 2 years. Male:female ratio 
was 3:1. Rashes were present in all the 27 cases (100%), and 
buttocks and lower limbs were the first to be affected. The time of 
onset of rashes was different. Rashes were the initial presenting 
clinical picture in 13 cases. In seven cases, fever (25%) and in 
seven others, and pain abdomen (25%) were noted before the 
appearance of rashes. In two cases, rashes were the only mode of 
presentation. The details are given in Table 1.
GI symptoms were seen in 8 patients (29%) which 
included vomiting (14%), organomegaly (14%), and scrotal 
swelling (7%). When the laboratory parameters were 
assessed (Table 2), the mean platelet count was found to be 
285,000 (240,000–540,000) L/mm3 and mean hemoglobin level 
was 7.5 (8.8–13 gm/dl). Antinuclear antibody and rheumatoid 
factor were done only in 20 patients out of which each one 
had single positive report. Antistreptolysin O titer of >200 was 
found in 8 (29%) patients. Abnormal urine analysis was noticed 
in 9 (33%) patients. Ultrasound abnormalities in the form of 
hepatosplenomegaly, jejunal thickening, mesenteric adenitis, 
collection of fluid in the pouch of Douglas were seen in 6 (22%). 
In one patient (3%), intussusception was also diagnosed.
In 12 patients, oral steroid was given at the dose of 2 mg/kg for 
2 weeks in tapering doses while two patients did not require any 
medication and recovered only with symptomatic management. 
Injectable steroids were required in 13 cases (Dexamethasone 
in 9 and methyl prednisolone in 4 patients) because of severe 
pain abdomen, persistent vomiting, unable to take oral steroid, 
and extensive rashes. Methyl prednisolone was given in the dose 
of 30 mg/kg/day for 3 days followed by oral steroids. Similarly, 
dexamethasone was given in the dose of 0.14 mg/kg/dose in 
divided doses for 5 days following which it was gradually tapered 
over 5 days. The details are given in Table 3.
Symptomatic improvement was seen in 83.3% cases with oral 
steroid within 72 h in comparison to injectable steroids in 61.5%. 
However, this difference is not statistically significant (p=0.378).
DISCUSSION
HSP is a small-vessel non granulomatous vasculitis. Deposition 
of IgA in the vessel wall, which is typical to this disease, 
leads to involvement of skin, joints, intestines, and kidneys. 
Children between 3 and 15 years are usually affected with male 
preponderance (male:female=1.5:1) [6,7]. The incidence is 
12–53 cases per 100,000 under 17 years.
The main clinical presentation of HSP is rash, pain abdomen 
with GI symptoms, joint pain, and sometimes renal involvement. 
In the present study, classical palpable purpura which is 
predominately seen in the lower extremities and buttocks was 
Table 1: Clinical profile
Clinical features Frequency (n=27) Percentage
Rashes 27 100
Abdominal pain 18 66
Vomiting 4 25
Hepatomegaly 2 7
Splenomegaly 2 7
Arthritis 12 44
Edema 13 48
Hypertension 1 3
Table 2: Laboratory parameters
Laboratory parameter n Frequency Percentage
Leukocytosis 27 21 77
High erythrocyte sedimentation rate 27 13 48
Anemia 27 8 29
Thrombocytosis 27 8 29
Antistreptolysin O (positive) 20 8 29
Antinuclear antibody 20 1 3
Rheumatoid factor 20 1 3
Hematuria 27 6 22
Proteinuria 27 3 11
Abnormal ultrasound abdomen 27 6 22
Table 3: Comparison between the oral and injectable steroids
Mode of 
treatment 
Response <72 h (%) Response >72 h p value
Oral steroids 10 (83.3) 2 (16.7) 0.378
Injectable steroids 8 (61.5) 5 (38.5)
Mishra et al. IgA vasculitis (HSP) in children
Vol 6 | Issue 9 | September 2019 Indian J Child Health 483
observed in all the cases. Similar results were observed by Kumar 
et al. [8,9]. Joint involvement, including arthritis and arthralgia is 
the second common presentation, occurring in up to 75% of the 
children with HSP. It was observed in 44% of the patients in our 
study and mainly affected ankle and knee joints.
The classical GI manifestations of HSP consist of nausea, 
vomiting, diarrhea, constipation, abdominal distension, 
periumbilical colicky, and abdominal pain due to edema 
and bleeding. Rare GI manifestations might include 
intestinal perforation, intussusceptions, esophageal ulcers, 
and pancreatitis which might require surgical intervention. 
According to a study by Choong and Beasley, the incidence 
of pain abdomen was 14–36% and in 11% cases, abdominal 
symptoms preceded the typical purpuric rashes. The incidence 
of intussusceptions was 4.6% [9]. In our study, only one 
(3%) patient developed intussusceptions for which surgical 
consultation was taken.
Various studies have reported scrotal involvement in HSP 
cases. The reported incidence of scrotal involvement ranges 
from 2 to 38%. Chao et al. reported 10% of acute scrotum at 
presentation [10]. In two of our cases, scrotal swelling was seen. 
Rashes and swelling in the joints developed 4–5 days after the 
scrotal swelling. Acute scrotal involvement might include scrotal 
rash and edema of scrotal soft tissue. It might be either unilateral 
or bilateral, and this pain mimics testicular torsion, though true 
torsion is rare. Hara et al. performed surgical exploration in 11 of 
their 25 HSP cases and did not identify testicular torsion in any of 
these patients [11].
Renal involvement was defined as the presence of gross 
or microscopic hematuria with or without proteinuria. The 
incidence of renal involvement varies from 10 to 50% with 
end-stage renal disease in 5%. Severe renal involvement might 
land up in long-term morbidity and mortality of HSP. Lardhi 
found renal involvement in 19 out of 78 (24%) patients [12]. In 
a study by Shah, the incidence of renal involvement was found 
to be 27% [13]. The outcome depends entirely on the extent of 
renal involvement. In our study, renal involvement was less in 
comparison to other studies.
Leukocytosis and elevated ESR are the usual hematological 
findings in HSP. The distinguishing feature from other forms of 
purpura is thrombocytosis [14]. The current study shows 29% 
thrombocytosis which correlates well with the other studies. 
Leukocytosis and elevated ESR were seen in 77% and 48%, 
respectively. In our study, none of the patients had central 
nervous system (CNS) involvement. Although this involvement 
is rare in HSP, in a study by Lava et al., CNS involvement 
presenting as posterior reversible encephalopathy syndrome 
(PRES) was mentioned, as a result of CNS vasculitis or arterial 
hypertension [15].
Supportive measures might be helpful in some of the patients 
with HSP. Corticosteroids help in reducing the duration and 
severity of abdominal and joint pain but, it does not alter the natural 
course of the disease. In general, prednisolone is a commonly used 
steroid for the treatment of HSP. Although 9 patients required 
injection dexamethasone for the treatment in our study, there 
is no evidence in literature to prove the superiority of one over 
the other. High dose steroid, azathioprine, cyclophosphamide, 
mycophenolate mofetil, intravenous Ig, and plasmapheresis 
might be needed in case of severe HSP nephritis [16,17].
The study had certain limitations. This was a retrospective 
study with small sample size. The involvement of multiple 
clinicians in the treatment prevented a standardized steroid 
therapy with respect to the type of the steroid and their dosage 
used. Second, most parents did not consent for the biopsy as it 
was an invasive procedure.
CONCLUSION
HSP appears to be common in the eastern part of our country. 
Spontaneous recovery with symptomatic management is also 
seen. The severity as well as involvement of renal system was 
less marked in our study. Corticosteroids seem to have a role 
in the management of HSP, but it does not alter the natural 
course of the disease. There is a requirement for large scale 
prospective study to establish the standardized treatment 
protocol for HSP.
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